Rapid induction of genes associated with tissue protection and neural development in contused adult spinal cord after radial glial cell transplantation., PMID:19257808
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation., PMID:19262067
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment., PMID:19365520
Topoisomerase II alpha is required for embryonic development and liver regeneration in zebrafish., PMID:19380487
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components., PMID:19479727
Aiming at the target: improved adjuvant medical therapy., PMID:19914538
Characterization of a novel, trastuzumab resistant human breast cancer cell line., PMID:20036907
Visualization of FISH Probes by dual-color chromogenic in situ hybridization., PMID:20093229
The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors., PMID:21614903
Biomarkers characterization of circulating tumour cells in breast cancer patients., PMID:22554015
Role of cell cycle biomarkers in human papillomavirus related uterine lesions., PMID:23016774
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation., PMID:23028939
Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer., PMID:23398928
Tumour expression of bladder cancer-associated urinary proteins., PMID:23470167
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study., PMID:24007746
MCM2/TOP2A (ProExC) immunohistochemistry as a predictive marker in head and neck mucosal biopsies., PMID:24630889
TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function., PMID:24658003
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study., PMID:25005255
Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization., PMID:25743022
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers., PMID:25777966
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma., PMID:25931012
Tyrosyl-DNA-phosphodiesterase I (TDP1) participates in the removal and repair of stabilized-Top2α cleavage complexes in human cells., PMID:26421495
Immunocytochemical study of TOP2A and Ki-67 in cervical smears from women under routine gynecological care., PMID:27175798
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer., PMID:27184134
Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions., PMID:27272799
Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer., PMID:27284123
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors., PMID:27557643
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy., PMID:27576528
Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer., PMID:27799773
Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue., PMID:28093271
Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features., PMID:28493257
ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review., PMID:28638271
A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma., PMID:28892521
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study., PMID:29530933
Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer., PMID:31072339
Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer., PMID:31251311
Discovering novel lung cancer associated antigens and the utilization of their autoantibodies in detection of lung cancer., PMID:31839396
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers., PMID:31949927
A panel of autoantibodies against tumor-associated antigens in the early immunodiagnosis of lung cancer., PMID:31980218
Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients., PMID:32024004
Predictive value of p16INK4a, Ki-67 and ProExC immuno-qualitative features in LSIL progression into HSIL., PMID:32256722
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study., PMID:33091733
Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis., PMID:33587914
Targeted Luminescent Probes for Precise Upconversion/NIR II Luminescence Diagnosis of Lung Adenocarcinoma., PMID:33705098
Functional differences and similarities in activated peripheral blood mononuclear cells by lipopolysaccharide or phytohemagglutinin stimulation between human and cynomolgus monkeys., PMID:33708884
Comparative Analysis on Abnormal Methylome of Differentially Expressed Genes and Disease Pathways in the Immune Cells of RA and SLE., PMID:34079550
Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis., PMID:35033076
Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease., PMID:37474274
Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry., PMID:38137396
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial., PMID:38453781
For research use only. Not for human or drug use.
